Stockreport

Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF The reported revenue represents a surprise of +3.39% over the Zacks Consensus Estimate of $710.89 million. With the consensus EPS estimate being $0.95, the EPS surprise [Read more]